WebJun 13, 2024 · Biogen and Alectos Therapeutics have signed an exclusive license and collaboration agreement to further develop and commercialize AL01811, a small … WebBiogen has entered into a license and collaboration agreement with Alectos Therapeutics to develop and commercialise AL01811 for the treatment of Parkinson’s Disease (PD). AL01811 is a new preclinical selective GBA2 inhibitor, which has first-in-class potential to be an oral disease modifying treatment for PD patients. The deal will combine ...

Biogen bets more than $700M on Alectos’ Parkinson’s drug

WebJul 5, 2024 · Biogen, Alectos Announce Licensing Agreement for Parkinson Disease GBA2 Inhibitor AL01811 Jul 5, 2024 Marco Meglio Alectos to receive a $15 million upfront … WebApr 10, 2024 · In June 2024, Biogen joined hands with Alectos Therapeutics to develop and commercialize a small molecule therapy known as AL01811, as a possible treatment for Parkinson’s disease. The collaboration will benefit Alectos with US$ 77.5 and US$ 630 Mn for development and commercial payments respectively. Moreover, Biogen will conduct … theory driving test booking ireland

Biogen and Alectos Therapeutics Announce License and …

WebToday we announced a new collaboration with Alectos Therapeutics Inc. to develop and commercialize an investigational drug for the potential treatment of ... Biogen in Boydton, VA WebWe are excited to collaborate with Alectos Therapeutics to research and develop a next generation oral GBA2 inhibitor for Parkinson’s Disease. Congrats and thank you to the Biogen and Alectos teams! theory driving test booking ni